Oxidative stress treatment for clinical trials in neurodegenerative diseases

Journal of Alzheimer's Disease

Volumn 24, Issue SUPPL. 2, 2011, Pages 111-126

  Ienco, Elena Caldarazzo ^a   Logerfo, Annalisa ^a   Carlesi, Cecilia ^a   Orsucci, Daniele ^a   Ricci, Giulia ^a   Mancuso, Michelangelo ^a   Siciliano, Gabriele ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Antioxidants; clinical trial; neurodegenerative diseases; oxidative stress

Indexed keywords

ALPHA TOCOPHEROL; ALPHA TOCOPHERYLQUINONE; ASCORBIC ACID; CARBON NANOTUBE; CAROTENOID; CROCIN; CYSTEINE; EPIGALLOCATECHIN GALLATE; FISH OIL; FLAVONOID; GELSOLIN; IDEBENONE; MECOBALAMIN; MEMANTINE; MEMBRANE PROTEIN; OMEGA 3 FATTY ACID; PIOGLITAZONE; PLACEBO; RESVERATROL; RETINOIC ACID; RILUZOLE; SELEGILINE; SELENIUM; SZETO SCHILLER PEPTIDE 31; THIOCTIC ACID; UBIDECARENONE; UBIQUINOL; UBIQUINONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; XANTHOPHYLL;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIOXIDANT ACTIVITY; CELL STRESS; DEGENERATIVE DISEASE; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FRIEDREICH ATAXIA; HUMAN; HUNTINGTON CHOREA; LOW DRUG DOSE; MITOCHONDRIAL MYOPATHY; MITOCHONDRION; NANOMEDICINE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VITAMIN SUPPLEMENTATION;

EID: 79955664287     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2011-110164     Document Type: Review

References (139)

1. Pangestuti R, Kim SK (2010) Neuroprotective properties of chitosan and its derivatives. Mar Drugs 8, 2117-2128.
2. Coppedè F, Mancuso M, Siciliano G, Migliore L, Murri L (2006) Genes and environment in neurodegeneration. Biosci Rep26, 341-367.
3. Mayeux R (2003) Epidemiology of neurodegeneration. Annu Rev Neurosci 26, 81-104. (Pubitemid 37064929)
4. Migliore L, Coppedè F (2002) Genetic and environmental factors in cancer and neurodegenerative diseases. Mutat Res 512, 135-153. (Pubitemid 35446305)
5. Brown RC, Lockwood AH, Sonawane BR (2005). Neurodegenerative diseases: an overview of environmental risk factors. Environ Health Perspect 113, 1250-1256. (Pubitemid 41387669)
6. Patten DA, Germain M, Kelly MA, Slack RS (2010) Reactive oxygen species: stuck in the middle of neurodegeneration. J Alzheimers Dis 20, 357-367.
7. Chaturvedi RK, Beal MF (2008) Mitochondrial approaches for neuroprotection. Ann N YAcad Sci 1147, 395-412.
8. Carri MT, Ferri A, Cozzolino M, Calabrese L, Rotilio G (2003) Neurodegeneration in amyotrophic lateral sclerosis: the role of oxidative stress and altered homeostasis of metals. Brain Res Bull 61, 365-374. (Pubitemid 36945467)
9. Coyle JT, Puttfarcken P (1993) Oxidative stress, glutamate, and neurodegenerative disorders. Science 262, 689-695. (Pubitemid 23350687)
10. Lenaz G (1998) Role of mitochondria in oxidative stress and ageing. Biochim Biophys Acta 1366, 53-67. (Pubitemid 28467022)
11. Halliwell B, Gutteridge JMC (1999) Free Radicals in Biology and Medicine 3 rd eds, Oxford Univ. Press, Oxford.
12. Yuan J, Yankner BA (2000) Apoptosis in the nervous system. Nature 407, 802-809.
13. Bjorklund A, Lindvall O (2000) Cell replacement therapies for central nervous system disorders. Nat Neurosci 3, 537-544. (Pubitemid 30332071)
14. Nunomura A, Honda K, Takeda A, Hirai K, Zhu X, Smith MA, Perry G (2006) Oxidative damage to RNA in neurodegenerative diseases. JBiomed Biotechnol 2006, 82323.
15. Halliwell B (1992) Reactive oxygen species and the central nervous system. JNeurochem 5, 1609-1623.
16. Chan DC (2006) Mitochondria: dynamic organelles in disease, aging, and development. Cell 125, 1241-1252. (Pubitemid 43929096)
17. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J (2007) Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 39, 44-84. (Pubitemid 44566469)
18. Miller RA, Britigan BE (1997) Role of oxidants in microbial pathophysiology. Clin Microbiol Rev 10, 1-18. (Pubitemid 27042829)
19. Groeger G, Quiney C, Cotter TG (2009) Hydrogen peroxide as a cell-survival signaling molecule. Antioxid Redox Signal 11, 2655-2671.
20. Qiongman Kong, Chien-liang Glenn Lin (2010) Oxidative damage to RNA: mechanisms, consequences, and diseases. Cell Mol Life Sci 67, 1817-1829
21. Navarro A, Boveris A (2010) Brain mitochondrial dysfunc-tion in aging, neurodegeneration, and Parkinson's disease. Front Aging Neurosci 2, 34.
22. Dalle-Donne I, Aldini G, Carini M, Colombo R, Rossi R, Milzani A (2006) Protein carbonylation, cellular dysfunc-tion, and disease progression. J Cell Mol Med 10, 389-406. (Pubitemid 44870187)
23. Nair U, Bartsch H, Nair J (2007) Lipid peroxidation-induced DNA damage in cancer-prone inflammatory diseases: a review of published adduct types and levels in humans. Free Radic Biol Med 43, 1109-1120. (Pubitemid 47374441)
24. Cadet J, Douki T, Gasparutto D, Ravanat JL (2003) Oxi-dative damage to DNA: formation, measurement and bio-chemical features. Mutat Res 531, 5-23. (Pubitemid 37456721)
25. Sies H (1993) Strategies of antioxidant defense. Eur J Biochem 215, 213-219. (Pubitemid 23224303)
26. Halliwell B (1995) Antioxidant characterization; methodol-ogy and mechanism. Biochem Pharmacol 49, 1341-1348.
27. Diplock AT, Charleux JL, Crozier-Willi G, Kok FJ, Rice-Evans C, Roberfroid M, Stahl W, Viña-Ribes J (1998) Functional food science and defence against reactive oxida-tive species. Br J Nutr 80, S77-S112.
28. Delanty N, Dichter MA (2000) Antioxidant therapy in neu-rologic disease. Arch Neurol 57, 1265-1270.
29. Aggarwal BB, Sundaram C, Prasad S, Kannappan R (2010) Tocotrienols, the vitamin E ofthe 21 st century: its potential against cancer and other chronic diseases. Biochem Phar-macol8, 1613-1631.
30. Hensley K, Benaksas EJ, Bolli R, Comp P, Grammas P, Hamdheydari L, Mou S, Pye QN, Stoddard MF, Wallis G, Williamson KS, West M, Wechter WJ, Floyd RA (2004) New perspectives on vitamin E: gammatocopherol and carboxyelthylhydroxychroman metabolites in biology and medicine. Free Radic Biol Med 36, 1-15. (Pubitemid 38068287)
31. Sen CK, Khanna S, Roy S (2006) Tocotrienols: vitamin E beyond tocopherols. Life Sci 78, 2088-2098.
32. Renuka Devi R, Arumughan C (2007) Antiradical efficacy of phytochemical extracts from defatted rice bran. Food Chem Toxicol 45, 2014-2021. (Pubitemid 47238217)
33. Lee SP, Mar GY, Ng LT (2009) Effects of tocotrienol-rich fraction on exercise endurance capacity and oxidative stress in forced swimming rats. Eur J Appl Physiol 107, 587-595.
34. Newaz MA, Nawal NN (1999) Effect of gamma-tocotrienol on blood pressure, lipid peroxidation and total antioxidant status in spontaneously hypertensive rats (SHR). Clin Exp Hypertens 21, 1297-313.
35. Hsieh TC, Wu JM (2008) Suppression of cell proliferation and gene expression by combinatorial synergy of EGCG, resveratrol and gamma-tocotrienol in estrogen receptor-positiveMCF-7 breastcancercells. Int J Oncol 33, 851-859.
36. Adam A, Marzuki A, Ngah WZ, Top GM (1996) Nitro-furantoin-induced hepatic and pulmonary biochemical changes in mice fed different vitamin E doses. Pharmacol Toxicol 79, 334-339. (Pubitemid 27008055)
37. Asensi-Fabado MA, Munné-Bosch S (2010) Vitamins in plants: occurrence, biosynthesis and antioxidant function. Trends Plant Sci 15, 582-592.
38. Carlsen MH, Halvorsen BL, Holte K, Bøhn SK, Dragland S, Sampson L, Willey C, Senoo H, Umezono Y, Sanada C, Barikmo I, Berhe N, Willett WC, Phillips KM, Jacobs DR Jr, Blomhoff R (2010) The total antioxidant content of more than 3100 foods, beverages, spices, herbs and supplements used worldwide. Nutr J 22, 9: 3.
39. Sen CK, Rink C, Khanna S (2010) Palm oil-derived natu-ral vitamin E alpha-tocotrienol in brain health and disease. J Am Coll Nutr 29, 314-323.
40. Suzuki YJ, Tsuchiya M, Wassall SR, Choo YM, Govil G, Kagan VE, Packer L (1993) Structural and dynamic mem-brane properties of alpha-tocopherol and alpha-tocotrienol: implication to the molecular mechanism oftheir antioxidant potency. Biochemistry 32, 10692-10699. (Pubitemid 23327802)
41. Khanna S, Roy S, Parinandi NL, Maurer M, Sen CK (2006) Characterization of the potent neuroprotective properties ofthe natural vitamin E alpha-tocotrienol. J Neurochem 98, 1474-1486. (Pubitemid 44200439)
42. Praticò D (2008) Evidence of oxidative stress in Alzheimer's disease brain and antioxidant therapy: lights and shadows. Ann N Y Acad Sci 1147, 70-78.
43. Dumont M, Lin MT, Beal MF (2010) Mitochondria and antioxidant targeted therapeutic strategies for Alzheimer's disease. J Alzheimers Dis 20, S633-S643.
44. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ (1997) A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 336, 1216-1222. (Pubitemid 27183651)
45. Morris MC, Beckett LA, Scherr PA, Hebert LE, Bennett DA, Field TS, Evans DA (1998) Vitamin E and vitamin C supple-ment use and risk of incident Alzheimer disease. Alzheimer Dis Assoc Disord 12, 121-126. (Pubitemid 29154978)
46. Masaki KH, Losonczy KG, Izmirlian G, Foley DJ, Ross GW, Petrovitch H, Havlik R, White LR (2000) Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology 54, 1265-1272. (Pubitemid 30174045)
47. Morris MC, Evans DA, Bienias JL, Tangney CC, Wilson RS (2002) Vitamin E and cognitive decline in older persons. Arch Neurol 59, 1125-1132. (Pubitemid 34755825)
48. Grodstein F, Chen J, Willett WC (2003) High-dose anti-oxidant supplements and cognitive function in community-dwelling elderly women. Am J Clin Nutr 77, 975-984.
49. Engelhart MJ, Geerlings MI, Ruitenberg A, van Swieten JC, Hofman A, Witteman JC, Breteler MM (2002) Dietary intake of antioxidants and risk of Alzheimer disease. JAMA 287, 3223-3229. (Pubitemid 34686103)
50. Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Aggarwal N, Wilson RS, Scherr PA (2002) Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA 287, 3230-3237. (Pubitemid 34686104)
51. Zandi PP, Anthony JC, Khachaturian AS, Stone SV, Gustafson D, Tschanz JT, Norton MC, Welsh-Bohmer KA, Breitner JC (2004) Reduced risk of Alzheimer disease in users of antioxidants vitamin supplements: The Cache County Study. Arch Neurol 61, 82-88. (Pubitemid 38067418)
52. Parnetti L, Ambrosoli L, Abate G, Azzini C, Balestreri R, Bartorelli L, Bordin A, Crepaldi G, Cristianini G, Cucinotta D, et al. (1995) Posatirelin for the treatment of late-onset Alzheimer's disease: a double-blind multicentre study vs citicoline and ascorbic acid. Acta Neurol Scand 92, 135-140.
53. Luchsinger JA, Tang MX, Shea S, Mayeux R (2003) Antiox-idant vitamin intake and risk of Alzheimer disease. Arch Neurol 60, 203-208. (Pubitemid 36193963)
54. Yaffe K, Clemons TE, McBee WL, Lindblad AS (2004) Impact of antioxidants, zinc, and copper on cognition in the elderly: a randomized, controlled trial. Neurology 63, 1705-1707. (Pubitemid 39507595)
55. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ; Alzheimer's Disease Cooperative Study Group (2005) Vitamin E and donezepil for the treatment of mild cognitive impairment. N Engl J Med 352, 2379-2388 (Pubitemid 40958434)
56. Clinicaltrials.gov, http://www.clinicaltrials.gov, Accessed February 23, 2011.
57. Butterfield DA, Castegna A, Drake J, Scapagnini G, Calabrese V (2002) Vitamin E and neurodegenerative dis-orders associated with oxidative stress. Nutr Neurosci 5, 229-239. (Pubitemid 34823459)
58. Parkinson Study Group (1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 328, 176-183.
59. Shoulson I (1989) Deprenyl and tocopherol antioxida-tive therapy of parkinsonism (DATATOP). Parkinson Study Group. Acta Neurol Scand Suppl 80, 171-175. (Pubitemid 20022092)
60. Hauser RA (2010) Early pharmacologic treatment in Parkin-son's disease. Am J Manag Care 16, S100-S107.
61. Kieburtz K, McDermott M, Como P, Growdon J, Brady J, Carter J, Huber S, Kanigan B, Landow E, Rudolph A, et al. (1994) The effect of deprenyl and tocopherol on cog-nitive performance in early untreated Parkinson's disease. Parkinson Study Group. Neurology 44, 1756-1759. (Pubitemid 24286662)
62. Zhang SM, Hernan MA, Chen H, Spiegelman D, Willett WC, Ascherio A (2001) Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk. Neurology 59, 1161-1169.
63. Di Donato I, Bianchi S, Federico A (2010) Ataxia with vita-min E deficiency: update of molecular diagnosis. Neurol Sci 31, 511-515.
64. Doria-Lamba L, De Grandis E, Cristiani E, Fiocchi I, Montaldi L, Grosso P, Gellera C (2006) Efficacious vita-min E treatment in a child with ataxia with isolated vitamin E deficiency. Eur J Pediatr 165, 494-495. (Pubitemid 43800533)
65. Reider CR, Paulson GW (1997) Lou Gehrig and amy-otrophic lateral sclerosis. Is vitamin E to be revisited? Arch Neurol 54, 527-528. (Pubitemid 27204237)
66. Orrell RW, Lane RJ, Ross M (2007) Antioxidant treat-ment for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 24, CD002829.
67. Petersen-Shay K, Shenvi S, Hagen TM (2008) Lipoic acid as an inducer of phase II detoxification enzymes through acti-vation of Nr-f2 dependent gene expression. In Alpha Lipoic Acid: Energy Production, Antioxidant Activity and Health Effects, Packer L, Patel M, eds. Taylor & Francis Publishers, Boca Raton, New York, London, pp. 349-371.
68. Lii CK, Liu KL, Cheng YP, Lin AH, Chen HW, Tsai CW (2010) Sulforaphane and-lipoic acid upregulate the expres-sion of the class of glutathione s-transferase through c-Jun and Nrf2 activation 1, 2. J Nutr 140, 885-892.
69. Rodriguez MC, MacDonald JR, Mahoney DJ, Parise G, Beal MF, Tarnopolsky MA (2000) Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. Muscle Nerve 35, 235-242.
70. Andreassen OA, Ferrante RJ, Dedeoglu A, Beal MF (2001) Lipoic acid improves survival in transgenic mouse models of Huntington's disease. Neuroreport 12, 3371-3373. (Pubitemid 33010674)
71. Andreassen OA, Dedeoglu A, Friedlich A, Ferrante KL, Hughes D, Szabo C, Beal MF (2001) Effects of an inhibitor of poly(ADP-ribose) polymerase, desmethylselegiline, tri-entine, and lipoic acid in transgenic ALS mice. Exp Neurol 168, 419-424. (Pubitemid 32289778)
72. Maczurek A, Hager K, Kenklies M, Sharman M, Martins R, Engel J, Carlson DA, Münch G (2008) Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer's disease. Adv Drug Deliv Rev 60, 1463-1470.
73. Spencer JP (2010) Beyond antioxidants: the cellular and molecular interactions of flavonoids and how these underpin their actions on the brain. Proc Nutr Soc 69, 244-260.
74. Manach C, Scalbert A, Morand C, Rémésy C, Jiménez L (2004) Polyphenols: food sources and bioavailability. Am J Clin Nutr 79, 727-747. (Pubitemid 41103873)
75. Gutierrez-Merino C, Lopez-Sanchez C, Lagoa R, Samhan-Arias AK, Bueno C, Garcia-Martinez V (2011) Neuroprotective actions of flavonoids. Curr Med Chem [Epub ahead ofprint].
76. Pollard SE, Kuhnle GG, Vauzour D, Vafeiadou K, Tzounis X, Whiteman M, Rice-Evans C, Spencer JP (2006) The reaction of flavonoid metabolites with peroxynitrite. Biochem Biophys Res Commun 350, 960-968. (Pubitemid 44584186)
77. Bagchi M, Milnes M, Williams C, Balmoori J, Ye X, Stohs S, Bagchi D (1999) Acute and chronic stress-induced oxidative gastrointestinal injury in rats, and the protective ability of a novel grape seed proanthocyanidin extract. Nutr Res 19, 1189-1199. (Pubitemid 29297745)
78. Galleano M, Verstraeten SV, Oteiza PI, Fraga CG (2010) Antioxidant actions of flavonoids: thermodynamic and kinetic analysis. Arch Biochem Biophys 501, 23-30.
79. Williams RJ, Spencer JPE, Rice-Evans C (2004) Flavonoids: antioxidants or signalling molecules? Free Radic Biol Med 36, 838-849. (Pubitemid 38352901)
80. Spencer JPE (2007) The interactions of flavonoids within neuronal signalling pathways. Gen Nutr 2, 257-273.
81. Spencer JPE (2008) Food for thought: the role of dietary flavonoids in enhancing human memory, learning and neuro-cognitive performance. Proc Nutr Soc 67, 238-252.
82. Kelsey NA, Wilkins HM, Linseman DA (2010) Nutraceutical antioxidants as novel neuroprotective agents. Molecules 15, 7792-7814.
83. Stahl W, Sies H (1993) Physical quenching of singlet-oxygen and cis-trans isomerization of carotenoids. Ann N Y Acad Sci691, 10-19. (Pubitemid 24099376)
84. Olson JA, Krinsky NI (1995) Introduction: the colorful fascinating world of carotenoids: important biological modulators. FEBS J9, 1547-1550.
85. Mangels AR, Holden JM, Beecher GR, Forman R, Lanza E (1993) Carotenoid content offruits and vegetables: an evaluation of analytic data. J Am Diet Assoc 93, 284-296. (Pubitemid 23070877)
86. Jama JW, Launer LJ, Witteman JC, den Breeijen JH, Breteler MM, Grobbee DE, Hofman A (1996) Dietary antioxidants and cognitive function in a population-based sample of older persons. The Rotterdam Study. Am J Epidemiol 144, 275-280. (Pubitemid 26313504)
87. Perrig WJ, Perrig P, Stahelin HB (1997) The relation between antioxidants and memory performance in the old and very old. J Am Geriatr Soc 45, 718-724. (Pubitemid 27248781)
88. Lee HP, Casadesus G, Zhu X, Lee HG, Perry G, Smith MA, Gustaw-Rothenberg K, Lerner A (2009) All-trans retinoic acid as a novel therapeutic strategy for Alzheimer's disease. Expert Rev Neurother 9, 1615-1621.
89. Khalili M, Hamzeh F (2010) Effects of active constituents of Crocus sativus L., crocin on streptozocin-induced model of sporadic Alzheimer's disease in male rats. Iran Biomed J14, 59-65.
90. Parasassi T, Brunelli R, Costa G, De Spirito M, Krasnowska E, Lundeberg T, Pittaluga E, Ursini F (2010) Thiol redox transitions in cell signaling: a lesson from N-acetylcysteine. Scientific World Journal 10, 1192-1202.
91. Lands LC, Grey VL, Smountas AA (1999) Effect of supplementation with a cysteine donor on muscular performance. J Appl Physiol 87, 1381-1385. (Pubitemid 29483123)
92. Witko-Sarsat V, Friedlander M, Capeillère-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, Jungers P, Descamps-Latscha B (1996) Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 49, 1304-1313. (Pubitemid 26166404)
93. Mancuso M, Orsucci D, Logerfo A, Rocchi A, Petrozzi L, Nesti C, Galetta F, Santoro G, Murri L, Siciliano G (2010) Oxidative stress biomarkers in mitochondrial myopathies, basally and after cysteine donor supplementation. J Neurol 257, 774-781.
94. Benzie IF, Strain JJ (1996) The ferric reducing ability of plasma (FRAP) as a measure of antioxidant power: the FRAP assay. Anal Biochem 239, 70-76.
95. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, O'Regan JP, Deng HX, et al. (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362, 59-62. (Pubitemid 23087289)
96. Zimmerman MC, Oberley LW, Flanagan SW (2007) Mutant SOD1-induced neuronal toxicity is mediated by increased mitochondrial superoxide levels. J Neurochem 102, 609-618. (Pubitemid 47057273)
97. Beal MF (2005) Mitochondriatake center stage in aging and neurodegeneration. Ann Neurol 58, 495-505. (Pubitemid 41377212)
98. Schulz JB, Lindenau J, Seyfried J, Dichgans J (2000) Glu-tathione, oxidative stress and neurodegeneration. Eur J Biochem 267, 4904-4911.
99. Bogaert E, d'Ydewalle C, Van Den Bosch L (2010) Amyo-trophic lateral sclerosis and excitotoxicity: from patholog-ical mechanism to therapeutic target. CNS Neurol Disord Drug Targets 9, 297-304.
100. Siciliano G, Carlesi C, Pasquali L, Piazza S, Pietracupa S, Fornai F, Ruggieri S, Murri L (2010) Clinical trials for neu-roprotection in ALS. CNS Neurol Disord Drug Targets 9, 305-313.
101. Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, Nakanishi A (1999)The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 169, 13-21 (Pubitemid 29502501)
102. Kwiatkowski DJ, Mehl R, Ying HL (1988) Genomic orga-nization and biosynthesis of secreted and cytoplasmic forms of gelsolin. J Cell Biol 106, 375-384. (Pubitemid 18052185)
103. Wen D, Corina K, Chow EP, Miller S, Janmey PA, Pepin-sky RB (1996) The plasma and cytoplasmic forms of human gelsolin differin disulfide structure. Biochemistry 35, 9700-9709. (Pubitemid 26302982)
104. Chauhan V, Ji L, Chauhan A (2008) Anti-amyloidogenic, anti-oxidant and anti-apoptotic role of gelsolin in Alzhei-mer's disease. Biogerontology 9, 381-389.
105. Ji L, Chauhan A, Chauhan V (2008) Cytoplasmic gelsolinin pheochromocytoma-12 cells forms a complex with amyloid beta-protein. Neuroreport 19, 463-466. (Pubitemid 351301606)
106. McDonagh B, Sheehan D (2007) Effect of oxidative stress on protein thiols in the blue mussel Mytilus edulis: pro-teomic identification of target proteins. Proteomics 7, 3395-3403. (Pubitemid 47517954)
107. Güntert A, Campbell J, Saleem M, O'Brien DP, Thompson AJ, Byers HL, Ward MA, Lovestone S (2010) Plasma gelsolin is decreased and correlates with rate of decline in Alzheimer's disease. J Alzheimers Dis 21, 585-596.
108. Turunen M, Olsson J, Dallner G (2004) Metabolism and function of coenzyme Q. Biochim Biophys Acta 1660, 171-199. (Pubitemid 38125244)
109. Bentinger M, Tekle M, Dallner G (2010) Coenzyme Q-biosynthesis and functions. Biochem Biophys Res Commun 396, 74-79.
110. Mancuso M, Orsucci D, Volpi L, Calsolaro V, Siciliano G (2010) Coenzyme Q10 in neuromuscular and neurodegen-erative disorders. Curr Drug Targets 11, 111-121.
111. Papucci L, Schiavone N, Witort E, Donnini M, Lapucci A, Tempestini A, Formigli L, Zecchi-Orlandini S, Orlandini G, Carella G, Brancato R, Capaccioli S (2003) Coenzyme q10 prevents apoptosis by inhibiting mitochondrial depolariza-tion independently of its free radical scavenging property. J Biol Chem 278, 28220-28228. (Pubitemid 36900022)
112. Weber CA, Ernst ME (2006) Antioxidants, supplements, and Parkinson's disease. Ann Pharmacother 40, 935-938. (Pubitemid 43765012)
113. Matthews RT, Yang L, Browne S, Baik M, Beal MF (1998) Coenzyme Q10 administration increases brain mitochon-drial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci USA 95, 8892-8897.
114. Smith KM, Matson S, Matson WR, Cormier K, DelSignore SJ, Hagerty SW, Stack EC, Ryu H, Ferrante RJ (2006) Dose ranging and efficacy study of high-dose coenzyme Q10 for-mulations in Huntington's disease mice. Biochim Biophys Acta 1762, 616-626. (Pubitemid 43903119)
115. Huntington Study Group (2001) A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 57, 397-404.
116. Cooper JM, Korlipara LV, Hart PE, Bradley JL, Schapira AH (2008) Coenzyme Q10 and vitamin E deficiency in Friedre-ich's ataxia: predictor of efficacy of vitamin E and coenzyme Q10therapy. Eur J Neurol 15, 1371-1379.
117. Di Prospero NA, Baker A, Jeffries N, Fischbeck KH (2007) Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial. Lancet Neurol 6, 878-886. (Pubitemid 47404985)
118. Cooper JM, Schapira AH (2007) Friedreich's ataxia: coen-zyme Q10 and vitamin E therapy. Mitochondrion (7 Suppl), S127-S135. (Pubitemid 46712240)
119. Senin U, Parnetti L, Barbagallo-Sangiorgi G, Bartorelli L, Bocola V, Capurso A, Cuzzupoli M, Denaro M, Marigliano V, Tammaro AE, Fioravanti M (1992) Idebenone in senile dementia of Alzheimer type: a multicentre study. Arch Gerontol Geriatr 15, 249-260. (Pubitemid 23016908)
120. Bergamasco B, Scarzella L, La Commare P (1994) Idebenone, a new drug in the treatment of cognitive impair-ment in patients with dementia of the Alzheimer type. Funct Neurol9, 161-168. (Pubitemid 24253315)
121. Weyer G, Babej-Dölle RM, Hadler D, Hofmann S, Her-rmann WM (1997) A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease. Neu-ropsychobiology 36, 73-82. (Pubitemid 27331264)
122. Gutzmann H, Hadler D (1998) Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study. JNeural Transm Suppl 54, 301-310. (Pubitemid 28539367)
123. Thal LJ, Grundman M, Berg J, Ernstrom K, Margolin R, Pfeiffer E, Weiner MF, Zamrini E, Thomas RG (2003) Idebenone treatment fails to slow cognitive decline in Alzheimer's disease. Neurology 61, 1498-1502. (Pubitemid 37505568)
124. Jauslin ML, Meier T, Smith RA, Murphy MP (2003) Mitochondria-targeted antioxidants protect Friedreich ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants. FASEB J 17, 1972-1974.
125. Lu C, Zhang D, Whiteman M, Armstrong JS (2007) Is antioxidant potential of the mitochondrial targeted ubiquinone derivative mitoq conserved in cells lacking mtDNA? Antioxid Redox Signal 10, 651-660.
126. Snow BJ, Rolfe FL, Lockhart MM, Frampton CM, O'Sullivan JD, Fung V, Smith RA, Murphy MP, Taylor KM; Protect Study Group (2010) A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkin-son's disease. Mov Disord 25, 1670-1674.
127. Armstrong JS (2007) Mitochondria-directed therapeutics. Antioxid Redox Signal 10, 575-578.
128. Zhao K, Zhao GM, Wu D, Soong Y, Birk AV, Schiller PW, Szeto HH (2004) Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochon-drial swelling, oxidative cell death, and reperfusion injury. J Biol Chem 279, 34682-34690. (Pubitemid 39318098)
129. Petri S, Kiaei M, Damiano M, Hiller A, Wille E, Manfredi G, Calingasan NY, Szeto HH, Beal MF (2006) Cell-permeable peptide antioxidants as a novel therapeutic approach in a mouse model of amyotrophic lateral sclerosis. JNeurochem 98, 1141-1148 (Pubitemid 44127789)
130. Yang L, Zhao K, Calingasan NY, Luo G, Szeto HH, Beal MF (2009) Mitochondria targeted peptides protect against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine neu-rotoxicity. Antioxid Redox Signal 11, 2095-2104.
131. Manczak M, Mao P, Calkins MJ, Cornea A, Reddy AP, Murphy MP, Szeto HH, Park B, Reddy PH (2010) Mitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer's disease neurons. J Alzheimers Dis 20, S609-S631.
132. Triplitt C, Cersosimo E, DeFronzo RA (2010) Pioglita-zone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment. Vasc Health Risk Manag 6, 671-690.
133. Skov V, Glintborg D, Knudsen S, Tan Q, Jensen T, Kruse TA, Beck-Nielsen H, Højlund K (2008) Pioglitazone enhances mitochondrial biogenesis and ribosomal protein biosynthe-sis in skeletal muscle in polycystic ovary syndrome. PLoS One 3, e 2466.
134. Marmolino D, Manto M, Acquaviva F, Vergara P, Ravella A, Monticelli A, Pandolfo M (2010) PGC-1alpha down-regulation affects the antioxidant response in Friedreich's ataxia. PLoS One 5, e10025.
135. St-Pierre J, Drori S, Uldry M, Silvaggi JM, Rhee J, Jäger S, Handschin C, Zheng K, Lin J, Yang W, Simon DK, Bachoo R, Spiegelman BM (2006) Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 127, 397-408. (Pubitemid 44572377)
136. Geldmacher DS, Fritsch T, McClendon MJ, Landreth G (2011) A randomized pilot clinical trial of the safety of pio-glitazone in treatment of patients with Alzheimer disease. Arch Neurol 68, 45-50.
137. Galano A (2010) Carbon nanotubes: promising agents against free radicals. Nanoscale 2, 373-380.
138. Cirillo G, Hampel S, Klingeler R, Puoci F, Iemma F, Curcio M, Parisi OI, Spizzirri UG, Picci N, Leonhardt A, Ritschel M, Büchner B (2011) Antioxidant multi-walled carbon nan-otubes by free radical grafting of gallic acid: new materials for biomedical applications. J Pharm Pharmacol 63, 179-88.
139. Montenegro L, Campisi A, Sarpietro MG, Carbone C, Acquaviva R, Raciti G, Puglisi G (2011) In vitro eval-uation of idebenone-loaded solid lipid nanoparticles for drug delivery to the brain. Drug Dev Ind Pharm. doi:10.3109/03639045.2010.539231